Validations Queue
108,318 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 14 of 44, 100 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.
Pending (total)
108,318
Reviewed
13
Filtered
4,344
page 14 / 44
Showing on page
100
Filters
URL params control source + min-similarity threshold
Bulk auto-confirm by similarity threshold
Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.
Source0 selected · 0 visible
Bulk action
| Sim | Doc | Source | Pred | Domain | Prior | |
|---|---|---|---|---|---|---|
| 0.60 | FDA NDA204114: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — NOVARTIS | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA208028: LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE) — INVAGEN PHARMS | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA219552: PEMIGATINIB (PEMIGATINIB) — SANDOZ INC | fda 2026-06-01 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA BLA125377: YERVOY (IPILIMUMAB) — BRISTOL MYERS SQUIBB | fda 2026-06-12 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA ANDA213988: VASOPRESSIN IN DEXTROSE 5% (VASOPRESSIN) — DR REDDYS | fda 2026-06-03 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA NDA208434: ALECENSA (ALECTINIB HYDROCHLORIDE) — HOFFMANN-LA ROCHE | fda 2026-06-11 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA ANDA204209: ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE (ACETAMINOPHEN) — PHARMOBEDIENT | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA204017: TWIRLA (ETHINYL ESTRADIOL) — AGILE | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA207152: TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN (ACETAMINOPHEN) — AUROBINDO PHARMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA088640: MEPERIDINE HYDROCHLORIDE (MEPERIDINE HYDROCHLORIDE) — BARR | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA040826: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — SUN PHARM INDS LTD | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA040419: ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — SPECGX LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA203573: OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN (ACETAMINOPHEN) — PH HEALTH | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA211023: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — WES PHARMA INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA040746: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — AMNEAL PHARMS NY | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA075824: BUTORPHANOL TARTRATE (BUTORPHANOL TARTRATE) — HIKMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA077471: HYDROMORPHONE HYDROCHLORIDE (HYDROMORPHONE HYDROCHLORIDE) — GENUS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA040260: OXYCODONE AND ASPIRIN (ASPIRIN) — SUN PHARM INDUSTRIES | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA203794: NUCYNTA (TAPENTADOL HYDROCHLORIDE) — COLLEGIUM PHARM INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA040910: OXYCODONE AND ASPIRIN (ASPIRIN) — EPIC PHARMA LLC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA200533: NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — COLLEGIUM PHARM INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA078769: OXYCODONE HYDROCHLORIDE AND IBUPROFEN (IBUPROFEN) — ACTAVIS ELIZABETH | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA209924: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — ELITE LABS INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA091393: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — AVANTHI INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA207108: HYDROMORPHONE HYDROCHLORIDE (HYDROMORPHONE HYDROCHLORIDE) — GENUS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA212429: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — AUROLIFE PHARMA LLC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA040777: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — AMNEAL PHARMS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA211535: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — CIPLA | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA211533: DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE (DAPAGLIFLOZIN) — MSN | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA207318: NUPLAZID (PIMAVANSERIN TARTRATE) — ACADIA PHARMS INC | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA207694: GLYCEROL PHENYLBUTYRATE (GLYCEROL PHENYLBUTYRATE) — LUPIN | fda 2026-04-30 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA216537: CARBIDOPA AND LEVODOPA (CARBIDOPA) — AUROBINDO PHARMA LTD | fda 2026-05-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA209224: LACOSAMIDE (LACOSAMIDE) — AUROBINDO PHARMA LTD | fda 2026-05-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA208058: LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE) — HERITAGE PHARMA AVET | fda 2026-05-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA219346: ANDA219346 ((unspecified)) — SANDOZ INC | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA BLA761069: IMFINZI (DURVALUMAB) — ASTRAZENECA UK LTD | fda 2026-05-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA214373: BRENZAVVY (BEXAGLIFLOZIN) — THERACOSBIO | fda 2026-06-03 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA077446: IRBESARTAN AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — SANDOZ | fda 2026-06-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA219413: ANDA219413 ((unspecified)) — TEVA PHARMACEUTICALS, INC. | fda 2026-06-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA201973: TRAMADOL HYDROCHLORIDE (TRAMADOL HYDROCHLORIDE) — IPCA LABS LTD | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA202348: MORPHINE SULFATE (MORPHINE SULFATE) — SPECGX LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA210211: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — WES PHARMA INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA213761: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — QUAGEN | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA207509: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — HIBROW HLTHCARE | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA213479: LEVORPHANOL TARTRATE (LEVORPHANOL TARTRATE) — NOVITIUM PHARMA | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA208593: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ABHAI LLC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA005010: DEMEROL (MEPERIDINE HYDROCHLORIDE) — QUAGEN | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA076855: HYDROMORPHONE HYDROCHLORIDE (HYDROMORPHONE HYDROCHLORIDE) — SPECGX LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA077449: FENTANYL-75 (FENTANYL) — DIFGEN PHARMS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA040241: METHADONE HYDROCHLORIDE (METHADONE HYDROCHLORIDE) — VISTAPHARM LLC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA076636: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ACTAVIS ELIZABETH | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA205702: TRAMADOL HYDROCHLORIDE (TRAMADOL HYDROCHLORIDE) — MACLEODS PHARMS LTD | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA BLA761166: BESREMI (ROPEGINTERFERON ALFA-2B-NJFT) — PHARMAESSENTIA CORP | fda 2026-06-26 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA202970: LEVONORGESTREL AND ETHINYL ESTRADIOL (ETHINYL ESTRADIOL) — XIROMED | fda 2026-06-25 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA BLA761263: LUNSUMIO VELO (MOSUNETUZUMAB-AXGB) — GENENTECH INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA BLA761263: LUNSUMIO VELO (MOSUNETUZUMAB-AXGB) — GENENTECH INC | fda 2026-06-18 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.60 | FDA ANDA217265: LENALIDOMIDE (LENALIDOMIDE) — QILU | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.60 | FDA ANDA219257: ANDA219257 ((unspecified)) — RENATA LIMITED | fda 2026-04-08 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.60 | FDA NDA217388: WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — ASTRAZENECA AB | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA074712: LACTULOSE (LACTULOSE) — CUMBERLAND PHARMS | fda 2026-04-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA216718: SKYCLARYS (OMAVELOXOLONE) — BIOGEN US | fda 2026-04-07 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.60 | FDA BLA761059: HADLIMA (ADALIMUMAB-BWWD) — SAMSUNG BIOEPIS CO LTD | fda 2026-04-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA BLA761068: CRYSVITA (BUROSUMAB-TWZA) — KYOWA KIRIN | fda 2026-04-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA219755: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE) — INVENTIA HEALTHCARE LIMITED | fda 2026-04-09 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA BLA761184: NGENLA (SOMATROGON-GHLA) — PFIZER IRELAND PHARMACEUTICALS | fda 2026-04-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA090508: FINASTERIDE (FINASTERIDE) — SUN PHARM | fda 2026-04-30 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA NDA019010: LUPRON (LEUPROLIDE ACETATE) — ABBVIE ENDOCRINE INC | fda 2026-05-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA208510: VYVANSE (LISDEXAMFETAMINE DIMESYLATE) — TAKEDA PHARMS USA | fda 2026-04-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA206194: IRBESARTAN (IRBESARTAN) — HISUN PHARM HANGZHOU | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA219869: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — HETERO LABS LTD V | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA209089: XYZAL ALLERGY 24HR (LEVOCETIRIZINE DIHYDROCHLORIDE) — CHATTEM SANOFI | fda 2026-05-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA NDA203049: ARGATROBAN (ARGATROBAN) — HIKMA PHARM CO LTD | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA219622: TRIMBOW (BECLOMETHASONE DIPROPIONATE) — CHIESI | fda 2026-05-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA NDA213756: KOSELUGO (SELUMETINIB SULFATE) — ASTRAZENECA | fda 2026-05-26 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.60 | FDA NDA202811: LINZESS (LINACLOTIDE) — ABBVIE | fda 2026-05-21 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA BLA761309: COLUMVI (GLOFITAMAB-GXBM) — GENENTECH INC | fda 2026-06-22 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.60 | FDA ANDA078790: DIVALPROEX SODIUM (DIVALPROEX SODIUM) — LUPIN | fda 2026-05-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA BLA761063: EMGALITY (GALCANEZUMAB-GNLM) — ELI LILLY AND CO | fda 2026-06-05 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.60 | FDA ANDA214470: HALOPERIDOL (HALOPERIDOL) — ALEMBIC | fda 2026-06-04 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA208869: RUXOLITINIB (RUXOLITINIB) — APOTEX INC | fda 2026-06-09 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.60 | FDA ANDA208809: MORPHINE SULFATE (MORPHINE SULFATE) — HIKMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA074951: BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — STEVENS J | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA213571: ISOTRETINOIN (ISOTRETINOIN) — UPSHER SMITH LABS | fda 2026-06-16 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA090535: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — SUN PHARM INDS INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA207418: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ASCENT PHARMS INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA040110: MEPERIDINE HYDROCHLORIDE (MEPERIDINE HYDROCHLORIDE) — HIKMA | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA213479: LEVORPHANOL TARTRATE (LEVORPHANOL TARTRATE) — NOVITIUM PHARMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA215138: BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE (ACETAMINOPHEN) — HIKMA | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA215138: BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE (ACETAMINOPHEN) — HIKMA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA040535: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — WATSON LABS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA219052: PERAMPANEL (PERAMPANEL) — TARO | fda 2026-06-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA200533: NUCYNTA ER (TAPENTADOL HYDROCHLORIDE) — COLLEGIUM PHARM INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA089673: ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — RHODES PHARMS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA075972: METFORMIN HYDROCHLORIDE (METFORMIN HYDROCHLORIDE) — CHARTWELL | fda 2026-06-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA208539: TICAGRELOR (TICAGRELOR) — MICRO LABS | fda 2026-04-27 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.60 | FDA ANDA079099: LAMOTRIGINE (LAMOTRIGINE) — GLENMARK PHARMS LTD | fda 2026-04-17 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA ANDA090124: ALENDRONATE SODIUM (ALENDRONATE SODIUM) — AUROBINDO PHARMA | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.60 | FDA ANDA209348: LENALIDOMIDE (LENALIDOMIDE) — DR REDDYS | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.60 | FDA NDA216964: IDVYNSO (DORAVIRINE) — MSD | fda 2026-04-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.60 | FDA NDA218390: INGREZZA SPRINKLE (VALBENAZINE TOSYLATE) — NEUROCRINE | fda 2026-04-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% |